My Watchlist

Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.

Recs

2

Gilead Hits the Jackpot With HCV Drug

By | More Articles
November 13, 2012 | Comments (0)

Gilead (Nasdaq: GILD  ) just released data for a new hepatitis C combination therapy, and the results are staggering: a 100% cure rate! The news sent the stock soaring more than 13% on Monday. In this video, Motley Fool health care analyst Brenton Flynn breaks down the market potential for Gilead's new therapy and talks about another company with similarly excellent results that will want a share of that market for itself.

Gilead's story is an exciting one, and there is a lot of action in the stock price at the moment. But, while you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

Jeff Fischer and team have demystified options. And they can rack up income like $1,030... $2,626... and $3,228 on a schedule you can set your watch by!
That's why we're glad to announce every single one of their closely guarded strategies is available to YOU during May and June – 100% FREE, no strings attached! Just enter your email address in the box below...

Brenton Flynn has no positions in the stocks mentioned above. Max Macaluso has no positions in the stocks mentioned above. The Motley Fool owns shares of Gilead Sciences and Johnson & Johnson. Motley Fool newsletter services recommend Gilead Sciences, Johnson & Johnson, and Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

DocumentId: 2109269, ~/Articles/ArticleHandler.aspx, 5/21/2013 4:18:46 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 15,387.58 52.30 0.34%
S&P 500 1,669.16 2.87 0.17%
NASD 3,502.12 5.69 0.16%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

5/21/2013 4:00 PM
GILD $56.47 Up +0.73 +1.31%
Gilead Sciences CAPS Rating: ****
VRTX $79.47 Up +2.09 +2.70%
Vertex Pharmaceuti… CAPS Rating: ***
JNJ $88.57 Up +0.56 +0.64%
Johnson & Johnson CAPS Rating: *****
ABT $37.71 Down -0.10 -0.26%
Abbott Laboratorie… CAPS Rating: *****

Advertisement